Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study
Current Oncology · 2023
DOI: 10.3390/curroncol30090611 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von Amanda M Moore und 18 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca (USA).
Abstract (Originalsprache)
Background
Durvalumab is approved for the treatment of adults with unresectable stage III non-small cell lung cancer (NSCLC) post-chemoradiotherapy (CRT). This real-world study describes patient characteristics and durvalumab treatment patterns (number of doses and therapy duration; treatment initiation delays, interruptions, discontinuations, and associated reasons) among VHA-treated patients.
Methods
This was a retrospective cohort study of adults with unresectable stage III NSCLC receiving durvalumab at the VHA between 1 January 2017 and 30 June 2020. Patient characteristics and treatment patterns were presented descriptively.
Results
A total of 935 patients were included (median age: 69 years; 95% males; 21% Blacks; 46% current smokers; 16% ECOG performance scores ≥ 2; 50% squamous histology). Durvalumab initiation was delayed in 39% of patients (n = 367). Among the 200 patients with recorded reasons, delays were mainly due to physician preference (20%) and CRT toxicity (11%). Overall, patients received a median (interquartile range) of 16 (7–24) doses of durvalumab over 9.0 (2.9–11.8) months. Treatment interruptions were experienced by 19% of patients (n = 180), with toxicity (7.8%) and social reasons (2.6%) being the most cited reasons. Early discontinuation occurred in 59% of patients (n = 551), largely due to disease progression (24.2%) and toxicity (18.2%).
Conclusions
These real-world analyses corroborate PACIFIC study results in terms of the main reasons for treatment discontinuation in a VHA population with worse prognostic factors, including older age, predominantly male sex, and poorer performance score. One of the main reasons for durvalumab initiation delays, treatment interruptions, or discontinuations was due to toxicities. Patients could benefit from improved strategies to prevent, identify, and manage CRT and durvalumab toxicities timely and effectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA.
- Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
- Audie L. Murphy Veterans Hospital, South Texas Veterans Health Care System, San Antonio, TX 78229, USA.
- MD Anderson Cancer Center, Houston, TX 77030, USA.
- AstraZeneca US Medical Affairs, Gaithersburg, MD 20878, USA.
- College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA.
ORCID-Profile: Kelly R Reveles, Kristin Hsieh, Christopher R Frei
Förderung
- AstraZeneca (USA)
Zitieren
APA
Moore, A. M., Nooruddin, Z., Reveles, K. R., Datta, P., Whitehead, J. M., Franklin, K., Alkadimi, M., Williams, M. H., Williams, R. A., Smith, S., Reichelderfer, R., Cotarla, I., Brannman, L., Frankart, A., Mulrooney, T., Hsieh, K., Simmons, D. J., Jones, X., & Frei, C. R. (2023). Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study. Current Oncology. https://doi.org/10.3390/curroncol30090611
Vancouver
Moore AM, Nooruddin Z, Reveles KR, Datta P, Whitehead JM, Franklin K, et al. Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study. Current Oncology. 2023. doi:10.3390/curroncol30090611
BibTeX
@article{Moore2023,
author = {Moore, Amanda M and Nooruddin, Zohra and Reveles, Kelly R and Datta, Paromita and Whitehead, Jennifer M and Franklin, Kathleen and Alkadimi, Munaf and Williams, Madison H and Williams, Ryan A and Smith, Sarah and Reichelderfer, Renee and Cotarla, Ion and Brannman, Lance and Frankart, Andrew and Mulrooney, Tiernan and Hsieh, Kristin and Simmons, Daniel J and Jones, Xavier and Frei, Christopher R},
title = {Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study},
journal = {Current Oncology},
year = {2023},
doi = {10.3390/curroncol30090611}
}
EUVIMED